SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Jemal A, Thomas A, Murray T, Thun M. Cancer statistics, 2002. CA Cancer J Clin. 2002; 52: 2347.
  • 2
    Advanced Colorectal Cancer Meta-Analysis Project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J Clin Oncol. 1992; 10: 896903.
  • 3
    Kohne CH, Schoffski P, Wilke H, et al. Effective biomodulation by leucovorin of high-dose infusion fluorouracil given as a weekly 24-hour infusion: results of a randomized trial in patients with advanced colorectal cancer. J Clin Oncol. 1998; 16: 418426.
  • 4
    Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet. 2000; 355: 10411047.
  • 5
    Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med. 2000; 343: 905914.
  • 6
    Giacchetti S, Perpoint B, Zidani R, et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol. 2000; 18: 136147.
  • 7
    de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000; 18: 29382947.
  • 8
    Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 2004; 22: 18.
  • 9
    Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53: 457481.
  • 10
    Goldberg RM, Sargent DJ, Morton RF, Mahoney MR, Krook JE, O'Connell MJ. Early detection of toxicity and adjustment of ongoing clinical trials: the history and performance of the North Central Cancer Treatment Group's real-time toxicity monitoring program. J Clin Oncol. 2002; 20: 45914596.
  • 11
    Rothenberg ML, Meropol NJ, Poplin EA, Van Cutsem E, Wadler S. Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel. J Clin Oncol. 2001; 19: 38013807.
  • 12
    Sargent DJ, Niedzwiecki D, O'Connell MJ, Schilsky RL. Recommendation for caution with irinotecan, fluorouracil, and leucovorin for colorectal cancer. N Engl J Med. 2001; 345: 144145; author reply, 146.
  • 13
    Goldberg RM, Kaufmann SH, Atherton P, et al. A Phase I study of sequential irinotecan and 5-fluorouracil/leucovorin. Ann Oncol. 2002; 13: 16741680.
  • 14
    Leichman CG, Fleming TR, Muggia FM, et al. Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group study. J Clin Oncol. 1995; 13: 13031311.
  • 15
    de Gramont A, Bosset JF, Milan C, et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol. 1997; 15: 808815.
  • 16
    Van Cutsem E, Szanto J, Roth A, et al. Evaluation of the addition of oxaliplatin to the same Mayo or German 5FU regimen in advanced refractory colorectal cancer [abstract]. Proc Am Soc Clin Oncol. 1999; 18: 234a.
  • 17
    Ravaioli A, Marangolo M, Pasquini E, et al. Bolus fluorouracil and leucovorin with oxaliplatin as first-line treatment in metastatic colorectal cancer. J Clin Oncol. 2002; 20: 25452550.
  • 18
    Comba Z, Blajman C, Richardet E, et al. A randomised Phase II study of oxaliplatin alone versus oxaliplatin combined with 5-fluorouracil and folinic acid (Mayo Clinic regimen) in previously untreated metastatic colorectal cancer patients. Eur J Cancer. 2001; 37: 10061013.
  • 19
    Hochster HS, Chachoua A, Speyer J, et al. Oxaliplatin with weekly bolus 5FU and low-dose leucovorin (bFOL) as first-line therapy of colorectal cancer; a Phase II study [abstract]. Proc Am Soc Clin Oncol. 2003; 22: 275.
  • 20
    Grothey A, Jordan O, Kellner C, et al. Randomized Phase II trial of capecitabine plus irinotecan vs capecitabine plus oxaliplatin as first-line therapy of advanced colorectal cancer [abstract]. Proc Am Soc Clin Oncol. 2003; 22: 255.
  • 21
    Van Cutsem E, Twelves C, Tabernero J, et al. Mature results of a multinational, Phase II trial of capecitabine plus oxaliplatin, an effective 1st line option for patients with metastatic colorectal cancer [abstract]. Proc Am Soc Clin Oncol. 2003; 22: 255.